Review



cdk2 polyclonal antibody  (Bioss)


Bioz Verified Symbol Bioss is a verified supplier
Bioz Manufacturer Symbol Bioss manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 94

    Structured Review

    Bioss cdk2 polyclonal antibody
    Cdk2 Polyclonal Antibody, supplied by Bioss, used in various techniques. Bioz Stars score: 94/100, based on 7 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/cdk2+polyclonal+antibody/bioss___bs-10726r?v=Bioss
    Average 94 stars, based on 7 article reviews
    cdk2 polyclonal antibody - by Bioz Stars, 2026-06
    94/100 stars

    Images



    Similar Products

    94
    Bioss cdk2 polyclonal antibody
    Cdk2 Polyclonal Antibody, supplied by Bioss, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/cdk2+polyclonal+antibody/bioss___bs-10726r?v=Bioss
    Average 94 stars, based on 1 article reviews
    cdk2 polyclonal antibody - by Bioz Stars, 2026-06
    94/100 stars
      Buy from Supplier

    cdk2  (Bioss)
    94
    Bioss cdk2
    PKF inhibits CRC cell growth by inducing apoptosis and cell cycle arrest. (A, B) Cell viability of HCT15 and HCT116 cells treated with PKF for 24 h. (C) Cell migration of HCT15 and HCT116 cells after PKF treatment for 24. (D) Colony formation of HCT15 and HCT116 cells following PKF treatment for 24 h. (E) Cell apoptosis analysis of HCT15 and HCT116 cells after 24 h of PKF treatment. (F, G) Cell cycle analysis in HCT15 and HCT116 cells following PKF treatment for 24 h. (H) Protein expression levels of cell cycle‐related proteins (Cyclin D1, Cyclin A2, CDK1, <t>CDK2,</t> CDK7) and apoptosis markers (c‐Caspase‐3, c‐Caspase‐8) in HCT15 and HCT116 cells treated with PKF for 24 h. (I, J) Cell viability of HCT15 and HCT116 cells treated with PKF alone or in combination with Z‐VAD‐FMK (Z‐VAD). *** p < 0.001, **** p < 0.0001; ns, not significant.
    Cdk2, supplied by Bioss, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/cdk2+polyclonal+antibody/pmc13045231-226-68-70?v=Bioss
    Average 94 stars, based on 1 article reviews
    cdk2 - by Bioz Stars, 2026-06
    94/100 stars
      Buy from Supplier

    94
    Bioss rabbit anti cdk2 antibody
    PKF inhibits CRC cell growth by inducing apoptosis and cell cycle arrest. (A, B) Cell viability of HCT15 and HCT116 cells treated with PKF for 24 h. (C) Cell migration of HCT15 and HCT116 cells after PKF treatment for 24. (D) Colony formation of HCT15 and HCT116 cells following PKF treatment for 24 h. (E) Cell apoptosis analysis of HCT15 and HCT116 cells after 24 h of PKF treatment. (F, G) Cell cycle analysis in HCT15 and HCT116 cells following PKF treatment for 24 h. (H) Protein expression levels of cell cycle‐related proteins (Cyclin D1, Cyclin A2, CDK1, <t>CDK2,</t> CDK7) and apoptosis markers (c‐Caspase‐3, c‐Caspase‐8) in HCT15 and HCT116 cells treated with PKF for 24 h. (I, J) Cell viability of HCT15 and HCT116 cells treated with PKF alone or in combination with Z‐VAD‐FMK (Z‐VAD). *** p < 0.001, **** p < 0.0001; ns, not significant.
    Rabbit Anti Cdk2 Antibody, supplied by Bioss, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/cdk2+polyclonal+antibody/pm41526672-59-0-12?v=Bioss
    Average 94 stars, based on 1 article reviews
    rabbit anti cdk2 antibody - by Bioz Stars, 2026-06
    94/100 stars
      Buy from Supplier

    95
    Cell Signaling Technology Inc rabbit polyclonal antibodies anti cdk2
    PKF inhibits CRC cell growth by inducing apoptosis and cell cycle arrest. (A, B) Cell viability of HCT15 and HCT116 cells treated with PKF for 24 h. (C) Cell migration of HCT15 and HCT116 cells after PKF treatment for 24. (D) Colony formation of HCT15 and HCT116 cells following PKF treatment for 24 h. (E) Cell apoptosis analysis of HCT15 and HCT116 cells after 24 h of PKF treatment. (F, G) Cell cycle analysis in HCT15 and HCT116 cells following PKF treatment for 24 h. (H) Protein expression levels of cell cycle‐related proteins (Cyclin D1, Cyclin A2, CDK1, <t>CDK2,</t> CDK7) and apoptosis markers (c‐Caspase‐3, c‐Caspase‐8) in HCT15 and HCT116 cells treated with PKF for 24 h. (I, J) Cell viability of HCT15 and HCT116 cells treated with PKF alone or in combination with Z‐VAD‐FMK (Z‐VAD). *** p < 0.001, **** p < 0.0001; ns, not significant.
    Rabbit Polyclonal Antibodies Anti Cdk2, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/cdk2+polyclonal+antibody/pmc12143771-256-10-15?v=Cell+Signaling+Technology+Inc
    Average 95 stars, based on 1 article reviews
    rabbit polyclonal antibodies anti cdk2 - by Bioz Stars, 2026-06
    95/100 stars
      Buy from Supplier

    94
    Bioss phospho cdk2 thr14
    PKF inhibits CRC cell growth by inducing apoptosis and cell cycle arrest. (A, B) Cell viability of HCT15 and HCT116 cells treated with PKF for 24 h. (C) Cell migration of HCT15 and HCT116 cells after PKF treatment for 24. (D) Colony formation of HCT15 and HCT116 cells following PKF treatment for 24 h. (E) Cell apoptosis analysis of HCT15 and HCT116 cells after 24 h of PKF treatment. (F, G) Cell cycle analysis in HCT15 and HCT116 cells following PKF treatment for 24 h. (H) Protein expression levels of cell cycle‐related proteins (Cyclin D1, Cyclin A2, CDK1, <t>CDK2,</t> CDK7) and apoptosis markers (c‐Caspase‐3, c‐Caspase‐8) in HCT15 and HCT116 cells treated with PKF for 24 h. (I, J) Cell viability of HCT15 and HCT116 cells treated with PKF alone or in combination with Z‐VAD‐FMK (Z‐VAD). *** p < 0.001, **** p < 0.0001; ns, not significant.
    Phospho Cdk2 Thr14, supplied by Bioss, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/cdk2+polyclonal+antibody/pmc10014284__mmc6-272-20-23?v=Bioss
    Average 94 stars, based on 1 article reviews
    phospho cdk2 thr14 - by Bioz Stars, 2026-06
    94/100 stars
      Buy from Supplier

    96
    Proteintech cdk2 polyclonal antibody
    The involvement of T cells with the combined treatment of NHWD-870 and BCG in TME (A) Schematic diagram showing the main workflow of the single-cell process. (B) Uniform Manifold Approximation and Projection (UMAP) plot of T cells/NK cells. (C) Proportions of cell-cycle phase in CD4 + T cells and CD8 + T cells under different treatment conditions. (D) Monocle2 trajectory plot of CD4 + T cells; the color represents cell-cycle phase. (E) The expression of Mki67 and Top2a along the pseudotime of CD4 + T cells; cells from different treatment group were marked by different color. (F) Monocle2 trajectory plot of CD8 + T cells; the color represents cell-cycle phase. (G) The expression of Mki67 and Top2a along the pseudotime of CD8 + T cells; cells from different treatment group were marked by different color. (H and I) Activated primary T cells were treated with 3 or 6 nM NHWD-870 or BCG for 72 h. Western blot was conducted to analyze the expression of cell cycle-associated proteins (p-CDK1, PHH3, <t>CDK2,</t> and Cyclin A2) and DNA damage-associated protein γ-H2AX. GAPDH was used as the reference of loading quantity of protein sample. Data depict one representative experiment of three independent experiments. (J) Representative pictures of melanoma sections from different treatments using multiple immunohistochemistry with anti-CD3 (green), anti-Cyclin A2 (red), and anti-PPH3 (cyan). Yellow arrows indicate examples of Cyclin A2 + CD3 + or PHH3 + CD3 + cells. Scale bars, 40 μm. (K) Quantitative analysis of the proportion of Cyclin A2 + CD3 + or PHH3 + CD3 + cells in whole sections. (L) Histogram of the proportion of Ki67 + cells in CD4 + and CD8 + T cells in tumor tissues by flow cytometry. Data are shown as mean ± SEM. p values were calculated by unpaired two-sided t test. ∗ p < 0.05; ∗∗ p < 0.01; ∗∗∗ p < 0.001; ∗∗∗∗ p < 0.0001. See also <xref ref-type=Figure S2 . " width="250" height="auto" />
    Cdk2 Polyclonal Antibody, supplied by Proteintech, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/cdk2+polyclonal+antibody/pmc11970395-28-0-4?v=Proteintech
    Average 96 stars, based on 1 article reviews
    cdk2 polyclonal antibody - by Bioz Stars, 2026-06
    96/100 stars
      Buy from Supplier

    90
    ABclonal Biotechnology rabbit polyclonal antibodies against cdk2, cdk4, and cyclin e1
    The involvement of T cells with the combined treatment of NHWD-870 and BCG in TME (A) Schematic diagram showing the main workflow of the single-cell process. (B) Uniform Manifold Approximation and Projection (UMAP) plot of T cells/NK cells. (C) Proportions of cell-cycle phase in CD4 + T cells and CD8 + T cells under different treatment conditions. (D) Monocle2 trajectory plot of CD4 + T cells; the color represents cell-cycle phase. (E) The expression of Mki67 and Top2a along the pseudotime of CD4 + T cells; cells from different treatment group were marked by different color. (F) Monocle2 trajectory plot of CD8 + T cells; the color represents cell-cycle phase. (G) The expression of Mki67 and Top2a along the pseudotime of CD8 + T cells; cells from different treatment group were marked by different color. (H and I) Activated primary T cells were treated with 3 or 6 nM NHWD-870 or BCG for 72 h. Western blot was conducted to analyze the expression of cell cycle-associated proteins (p-CDK1, PHH3, <t>CDK2,</t> and Cyclin A2) and DNA damage-associated protein γ-H2AX. GAPDH was used as the reference of loading quantity of protein sample. Data depict one representative experiment of three independent experiments. (J) Representative pictures of melanoma sections from different treatments using multiple immunohistochemistry with anti-CD3 (green), anti-Cyclin A2 (red), and anti-PPH3 (cyan). Yellow arrows indicate examples of Cyclin A2 + CD3 + or PHH3 + CD3 + cells. Scale bars, 40 μm. (K) Quantitative analysis of the proportion of Cyclin A2 + CD3 + or PHH3 + CD3 + cells in whole sections. (L) Histogram of the proportion of Ki67 + cells in CD4 + and CD8 + T cells in tumor tissues by flow cytometry. Data are shown as mean ± SEM. p values were calculated by unpaired two-sided t test. ∗ p < 0.05; ∗∗ p < 0.01; ∗∗∗ p < 0.001; ∗∗∗∗ p < 0.0001. See also <xref ref-type=Figure S2 . " width="250" height="auto" />
    Rabbit Polyclonal Antibodies Against Cdk2, Cdk4, And Cyclin E1, supplied by ABclonal Biotechnology, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/cdk2+polyclonal+antibody/10__3390_slash_ijms26041474-276-5-18?v=ABclonal+Biotechnology
    Average 90 stars, based on 1 article reviews
    rabbit polyclonal antibodies against cdk2, cdk4, and cyclin e1 - by Bioz Stars, 2026-06
    90/100 stars
      Buy from Supplier

    Image Search Results


    PKF inhibits CRC cell growth by inducing apoptosis and cell cycle arrest. (A, B) Cell viability of HCT15 and HCT116 cells treated with PKF for 24 h. (C) Cell migration of HCT15 and HCT116 cells after PKF treatment for 24. (D) Colony formation of HCT15 and HCT116 cells following PKF treatment for 24 h. (E) Cell apoptosis analysis of HCT15 and HCT116 cells after 24 h of PKF treatment. (F, G) Cell cycle analysis in HCT15 and HCT116 cells following PKF treatment for 24 h. (H) Protein expression levels of cell cycle‐related proteins (Cyclin D1, Cyclin A2, CDK1, CDK2, CDK7) and apoptosis markers (c‐Caspase‐3, c‐Caspase‐8) in HCT15 and HCT116 cells treated with PKF for 24 h. (I, J) Cell viability of HCT15 and HCT116 cells treated with PKF alone or in combination with Z‐VAD‐FMK (Z‐VAD). *** p < 0.001, **** p < 0.0001; ns, not significant.

    Journal: Advanced Science

    Article Title: Homoisoflavanone Delays Colorectal Cancer Progression via DNA Damage‐Induced Mitochondrial Apoptosis and Parthanatos‐Like Cell Death

    doi: 10.1002/advs.202511406

    Figure Lengend Snippet: PKF inhibits CRC cell growth by inducing apoptosis and cell cycle arrest. (A, B) Cell viability of HCT15 and HCT116 cells treated with PKF for 24 h. (C) Cell migration of HCT15 and HCT116 cells after PKF treatment for 24. (D) Colony formation of HCT15 and HCT116 cells following PKF treatment for 24 h. (E) Cell apoptosis analysis of HCT15 and HCT116 cells after 24 h of PKF treatment. (F, G) Cell cycle analysis in HCT15 and HCT116 cells following PKF treatment for 24 h. (H) Protein expression levels of cell cycle‐related proteins (Cyclin D1, Cyclin A2, CDK1, CDK2, CDK7) and apoptosis markers (c‐Caspase‐3, c‐Caspase‐8) in HCT15 and HCT116 cells treated with PKF for 24 h. (I, J) Cell viability of HCT15 and HCT116 cells treated with PKF alone or in combination with Z‐VAD‐FMK (Z‐VAD). *** p < 0.001, **** p < 0.0001; ns, not significant.

    Article Snippet: The membranes were then blocked with a 5% non‐fat milk TBST (TBS containing 0.1% Tween‐20) for 1 h at room temperature and incubated at 4°C for overnight with primary antibodies against the following proteins: cleaved Caspase 3 (25128‐1‐AP, Proteintech), cleaved Caspase 8 (9496, CST), PARP (9542, CST), cleaved PARP (9541, CST), P21 (2947, CST), P53 (2527, CST), Cyclin A2 (91500, CST), Cyclin D1 (2978, CST), CDK1 (bs‐1341R, Bioss), CDK2 (bs‐10726R, Bioss), CDK7 (bs‐0569R, Bioss), AKT (4691, CST), p‐AKT (4060, CST), ERK (9102, CST), p‐ERK (9101, CST), MEK (9126, CST), p‐MEK (9154, CST), ATR (13934, CST), p‐ATR (2853, CST), Chk1 (2360, CST), p‐Chk1 (2348, CST), RAD51 (14961‐1‐AP, Proteintech), ATM (27156‐1‐AP, Proteintech), p‐ATM (5883, CST), γ‐H2AX (9718, CST), AIF (5318, CST), MIF (75038, CST), Cyt c (10993‐1‐AP, Proteintech), Lamin B (66095‐1‐Ig, Proteintech), VDAC1 (81538‐1‐RR, Proteintech) and GAPDH (60004‐1‐Ig, Proteintech).

    Techniques: Migration, Cell Cycle Assay, Expressing

    HIF inhibits CRC cells growth. (A, B) Cell viability of HCT15 and HCT116 cells treated with trans‐coumaroyltyramine (trans‐Coum), N‐feruloyloctopamine (Feru), N‐trans‐feruloyltyramine (trans‐Feru), disporopsin (Disp), or HIF for 24 h. (C) IC50 values of HIF in HCT15 and HCT116 cells. (D) Cell migration analysis of HCT15 and HCT116 cells following HIF treatment. (E) Colony formation assessment of HCT15 and HCT116 cells after HIF treatment for 24 h. (F) Apoptosis analysis of HCT15 and HCT116 cells after 24 h of HIF treatment. (G, H) Cell cycle distribution analysis of HCT15 and HCT116 cells following HIF treatment for 24 h. (I) Expression levels of cell cycle proteins (Cyclin D1, Cyclin A2, CDK1, CDK2, CDK7) and apoptosis markers (c‐Caspase3, c‐Caspase8). (J, K) The impact of Z‐VAD‐FMK (Z‐VAD) co‐treatment on HIF‐induced cell death in HCT15 and HCT116 cells. ** p < 0.01, *** p < 0.001, **** p < 0.0001; ns, not significant.

    Journal: Advanced Science

    Article Title: Homoisoflavanone Delays Colorectal Cancer Progression via DNA Damage‐Induced Mitochondrial Apoptosis and Parthanatos‐Like Cell Death

    doi: 10.1002/advs.202511406

    Figure Lengend Snippet: HIF inhibits CRC cells growth. (A, B) Cell viability of HCT15 and HCT116 cells treated with trans‐coumaroyltyramine (trans‐Coum), N‐feruloyloctopamine (Feru), N‐trans‐feruloyltyramine (trans‐Feru), disporopsin (Disp), or HIF for 24 h. (C) IC50 values of HIF in HCT15 and HCT116 cells. (D) Cell migration analysis of HCT15 and HCT116 cells following HIF treatment. (E) Colony formation assessment of HCT15 and HCT116 cells after HIF treatment for 24 h. (F) Apoptosis analysis of HCT15 and HCT116 cells after 24 h of HIF treatment. (G, H) Cell cycle distribution analysis of HCT15 and HCT116 cells following HIF treatment for 24 h. (I) Expression levels of cell cycle proteins (Cyclin D1, Cyclin A2, CDK1, CDK2, CDK7) and apoptosis markers (c‐Caspase3, c‐Caspase8). (J, K) The impact of Z‐VAD‐FMK (Z‐VAD) co‐treatment on HIF‐induced cell death in HCT15 and HCT116 cells. ** p < 0.01, *** p < 0.001, **** p < 0.0001; ns, not significant.

    Article Snippet: The membranes were then blocked with a 5% non‐fat milk TBST (TBS containing 0.1% Tween‐20) for 1 h at room temperature and incubated at 4°C for overnight with primary antibodies against the following proteins: cleaved Caspase 3 (25128‐1‐AP, Proteintech), cleaved Caspase 8 (9496, CST), PARP (9542, CST), cleaved PARP (9541, CST), P21 (2947, CST), P53 (2527, CST), Cyclin A2 (91500, CST), Cyclin D1 (2978, CST), CDK1 (bs‐1341R, Bioss), CDK2 (bs‐10726R, Bioss), CDK7 (bs‐0569R, Bioss), AKT (4691, CST), p‐AKT (4060, CST), ERK (9102, CST), p‐ERK (9101, CST), MEK (9126, CST), p‐MEK (9154, CST), ATR (13934, CST), p‐ATR (2853, CST), Chk1 (2360, CST), p‐Chk1 (2348, CST), RAD51 (14961‐1‐AP, Proteintech), ATM (27156‐1‐AP, Proteintech), p‐ATM (5883, CST), γ‐H2AX (9718, CST), AIF (5318, CST), MIF (75038, CST), Cyt c (10993‐1‐AP, Proteintech), Lamin B (66095‐1‐Ig, Proteintech), VDAC1 (81538‐1‐RR, Proteintech) and GAPDH (60004‐1‐Ig, Proteintech).

    Techniques: Migration, Expressing

    The involvement of T cells with the combined treatment of NHWD-870 and BCG in TME (A) Schematic diagram showing the main workflow of the single-cell process. (B) Uniform Manifold Approximation and Projection (UMAP) plot of T cells/NK cells. (C) Proportions of cell-cycle phase in CD4 + T cells and CD8 + T cells under different treatment conditions. (D) Monocle2 trajectory plot of CD4 + T cells; the color represents cell-cycle phase. (E) The expression of Mki67 and Top2a along the pseudotime of CD4 + T cells; cells from different treatment group were marked by different color. (F) Monocle2 trajectory plot of CD8 + T cells; the color represents cell-cycle phase. (G) The expression of Mki67 and Top2a along the pseudotime of CD8 + T cells; cells from different treatment group were marked by different color. (H and I) Activated primary T cells were treated with 3 or 6 nM NHWD-870 or BCG for 72 h. Western blot was conducted to analyze the expression of cell cycle-associated proteins (p-CDK1, PHH3, CDK2, and Cyclin A2) and DNA damage-associated protein γ-H2AX. GAPDH was used as the reference of loading quantity of protein sample. Data depict one representative experiment of three independent experiments. (J) Representative pictures of melanoma sections from different treatments using multiple immunohistochemistry with anti-CD3 (green), anti-Cyclin A2 (red), and anti-PPH3 (cyan). Yellow arrows indicate examples of Cyclin A2 + CD3 + or PHH3 + CD3 + cells. Scale bars, 40 μm. (K) Quantitative analysis of the proportion of Cyclin A2 + CD3 + or PHH3 + CD3 + cells in whole sections. (L) Histogram of the proportion of Ki67 + cells in CD4 + and CD8 + T cells in tumor tissues by flow cytometry. Data are shown as mean ± SEM. p values were calculated by unpaired two-sided t test. ∗ p < 0.05; ∗∗ p < 0.01; ∗∗∗ p < 0.001; ∗∗∗∗ p < 0.0001. See also <xref ref-type=Figure S2 . " width="100%" height="100%">

    Journal: Cell Reports Medicine

    Article Title: BET inhibitor in combination with BCG vaccine enhances antitumor efficacy and orchestrates T cell reprogramming for melanoma

    doi: 10.1016/j.xcrm.2025.101995

    Figure Lengend Snippet: The involvement of T cells with the combined treatment of NHWD-870 and BCG in TME (A) Schematic diagram showing the main workflow of the single-cell process. (B) Uniform Manifold Approximation and Projection (UMAP) plot of T cells/NK cells. (C) Proportions of cell-cycle phase in CD4 + T cells and CD8 + T cells under different treatment conditions. (D) Monocle2 trajectory plot of CD4 + T cells; the color represents cell-cycle phase. (E) The expression of Mki67 and Top2a along the pseudotime of CD4 + T cells; cells from different treatment group were marked by different color. (F) Monocle2 trajectory plot of CD8 + T cells; the color represents cell-cycle phase. (G) The expression of Mki67 and Top2a along the pseudotime of CD8 + T cells; cells from different treatment group were marked by different color. (H and I) Activated primary T cells were treated with 3 or 6 nM NHWD-870 or BCG for 72 h. Western blot was conducted to analyze the expression of cell cycle-associated proteins (p-CDK1, PHH3, CDK2, and Cyclin A2) and DNA damage-associated protein γ-H2AX. GAPDH was used as the reference of loading quantity of protein sample. Data depict one representative experiment of three independent experiments. (J) Representative pictures of melanoma sections from different treatments using multiple immunohistochemistry with anti-CD3 (green), anti-Cyclin A2 (red), and anti-PPH3 (cyan). Yellow arrows indicate examples of Cyclin A2 + CD3 + or PHH3 + CD3 + cells. Scale bars, 40 μm. (K) Quantitative analysis of the proportion of Cyclin A2 + CD3 + or PHH3 + CD3 + cells in whole sections. (L) Histogram of the proportion of Ki67 + cells in CD4 + and CD8 + T cells in tumor tissues by flow cytometry. Data are shown as mean ± SEM. p values were calculated by unpaired two-sided t test. ∗ p < 0.05; ∗∗ p < 0.01; ∗∗∗ p < 0.001; ∗∗∗∗ p < 0.0001. See also Figure S2 .

    Article Snippet: CDK2 Polyclonal antibody , Proteintech , Cat#10122-1-AP; RRID: AB_2078556.

    Techniques: Expressing, Western Blot, Immunohistochemistry, Flow Cytometry

    Journal: Cell Reports Medicine

    Article Title: BET inhibitor in combination with BCG vaccine enhances antitumor efficacy and orchestrates T cell reprogramming for melanoma

    doi: 10.1016/j.xcrm.2025.101995

    Figure Lengend Snippet:

    Article Snippet: CDK2 Polyclonal antibody , Proteintech , Cat#10122-1-AP; RRID: AB_2078556.

    Techniques: Recombinant, Control, Staining, Polymer, Multiplex Assay, Protease Inhibitor, Transfection, Gentle, Bicinchoninic Acid Protein Assay, Chromatin Immunoprecipitation, Magnetic Beads, Software